- BP1200, a novel antibody targeting CD73, improves the tumor microenvironment and activates anti-tumor immunity
- CD73 plays a central role in the generation of adenosine in tumors, which suppresses intra-tumor immune cells and decreases anti-tumor immune activity
- CD73 is highly expressed in many types of tumors, and is associated with poor prognosis
BP1200 is a humanized antibody that is a potentially best-in-class immune checkpoint inhibitor targeting CD73 expressed on tumor and immune cells. CD73 is a cell surface enzyme expressed on tumor cells that converts extracellular adenosine monophosphate (AMP) to immunosuppressive adenosine. Adenosine production inhibits T-cell and NK-cell cytotoxicity, cytokine production, and proliferation, as well as suppresses antigen-presenting cells and macrophage M2 polarization, enabling tumor growth and disease progression.
BP1200 ameliorates the suppressive tumor microenvironment by attenuating adenosine production and restores a broad anti-tumor response mediated by tumor infiltrating T cells, including enhancement of T-cell proliferation, cytokine production, and cytotoxicity.
BP1200 in combination with other complementary immune pathways such as PD-1/PD-L1, is a key strategy to enhance the anti-tumor cytotoxic potential of immunotherapy.
A novel anti-CD73 therapeutic antibody that ameliorates the tumor microenvironment and improves the efficacy of cancer immunotherapy
A novel therapeutic antibody against CD73 that ameliorates the tumor microenvironment and improves the efficacy of cancer immunotherapy